Compare Amphastar Pharmaceuticals Inc (AMPH) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Beyond Meat Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Beyond Meat Inc trades at $0.43 (market cap $268.23M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 3.2× Beyond Meat Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | BYND | |
|---|---|---|
Market Cap | $863.95M | $268.23M |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $3.62 |
52-Week Low | $16.87 | $0.52 |
Enterprise Value | $1.26B | $508.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
BYND trades at $0.5377, up 1.93% today, but remains in a deep bearish technical trend with weak sentiment. The company reported a surprising net income of $178M in 2025 after years of losses, though revenue continues to decline. Recent Q2 2026 earnings showed a smaller loss than expected, with management focusing on international expansion and new product launches like Beyond Steak Filet to drive a turnaround.
The outlook remains challenging with declining revenue, negative operating cash flow, and heavy reliance on financing. Analyst consensus is overwhelmingly bearish with 57% sell ratings. Key risks include execution of the turnaround strategy, intense competition, and persistent cash burn. The stock presents high risk with potential reward contingent on successful business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
